Macrophage migration inhibitory factor (MIF) promotes cell survival by activation of the Akt pathway and role for CSN5/JAB1 in the control of autocrine MIF activity
The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
The phosphoinositide-3-kinase (PI3K)/Akt signaling pathway plays an important role in cell survival and the development of cancer. Macrophage migration inhibitory factor (MIF) is a critical inflammatory cytokine that was recently associated with tumorigenesis and that potently inhibits apoptosis. This may involve inhibition of p53-dependent genes, but the initiating molecular mechanism of how MIF controls survival/apoptosis is unknown. Here, we show that MIF prevents apoptosis and promotes tumor cell survival by directly activating the Akt pathway. MIF enhanced Akt activity in primary and immortalized fibroblasts (MEF and NIH/3T3), HeLa cervix carcinoma cells and various breast cancer cell lines. Activation was abolished by kinase inhibitors Ly294002 and PP2 and in Src/Yes/Fyn(SYF)(-/-) and CD74(-/-)(MEFs), while being enhanced in CD74-overexpressing MEFs, demonstrating that the MIF-induced Akt pathway encompasses signaling through the MIF receptor CD74 and the upstream kinases Src and PI3K. Akt was activated by exogenous rMIF and autocrine MIF action, as revealed by experiments in MIF(-/-)MEFs and antibody blockade. siRNA knockdown of CSN5/JAB1, a tumor marker and MIF-binding protein, showed that JAB1 controls autocrine MIF-mediated Akt signaling by inhibition of MIF secretion. Akt activation by MIF led to phosphorylation of the proapoptotic proteins BAD and Foxo3a. Apoptosis inhibition by MIF was functionally associated with Akt activation as it was abolished by overexpression of the Akt pathway inhibitor PTEN and occurred independently of p53. This was shown by studying DNA damage-induced apoptosis in fibroblasts, the Fas death pathway in HeLa cells that do not express functional p53, and etoposide-induced apoptosis in breast carcinoma cells expressing mutant p53. Importantly, dependence of breast cancer cell survival on MIF correlated with Akt activation and the PTEN status of these cells. Thus, MIF can directly promote cell survival through activation of the PI3K/Akt pathway and this effect is critical for tumor cell survival.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“MIF is elevated in the AD brain and mediates pro-inflammatory signaling by promoting the secretion of IL-6 and TNF-α [46].”
From Abnormal accumulation of extracellular vesicles in hippocampal dystrophic axons and regulation by the primary cilia in Alzheimer's disease (2023) · cites this paper as [46]
Citations
Cites
Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery
Hennessy, B. T., Smith, D. L., Ram, P. T., Lu, Y., & Mills, G. B. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1902 · Cited by 2,185
The activation of Akt/PKB signaling pathway and cell survival
Song, G., Ouyang, G., & Bao, S. (2005) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2005.tb00337.x · Cited by 1,888
Macrophage migration inhibitory factor: a regulator of innate immunity
Calandra, T., & Roger, T. (2003) · Nature Reviews Immunology · doi:10.1038/nri1200 · Cited by 1,795
PI3K-Akt pathway: Its functions and alterations in human cancer
Osaki, M., Oshimura, M., & Ito, H. (2004) · Apoptosis · doi:10.1023/b:appt.0000045801.15585.dd · Cited by 1,264
Chang, F., Lee, J. T., Navolanic, P. M., Steelman, L. S., Shelton, J. G., Blalock, W. L., Franklin, R. A., & McCubrey, J. A. (2003) · Leukemia · doi:10.1038/sj.leu.2402824 · Cited by 1,176
MIF Signal Transduction Initiated by Binding to CD74
Leng, L., Metz, C. N., Fang, Y., Xu, J., Donnelly, S., Baugh, J., Delohery, T., Chen, Y., Mitchell, R. A., & Bucala, R. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030286 · Cited by 1,154
Self-citationRole of Akt Signaling in Vascular Homeostasis and Angiogenesis
Shiojima, I., & Walsh, K. (2002) · Circulation Research · doi:10.1161/01.res.0000022200.71892.9f · Cited by 1,012
MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia
Bernhagen, J., Calandra, T., Mitchell, R. A., Martin, S. B., Tracey, K. J., Voelter, W., Manogue, K. R., Cerami, A., & Bucala, R. (1993) · Nature · doi:10.1038/365756a0 · Cited by 999
Self-citationAngiogenic and cell survival functions of Vascular Endothelial Growth Factor (VEGF)
Byrne, A. M., Bouchier-Hayes, D. J., & Harmey, J. H. (2005) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2005.tb00379.x · Cited by 744
Mechanism of activation and function of protein kinase B
Alessi, D. R., & Cohen, P. (1998) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(98)80062-2 · Cited by 743
Cited by
McArdle, M. A., Finucane, O. M., Connaughton, R. M., McMorrow, A. M., & Roche, H. M. (2013) · Frontiers in Endocrinology · doi:10.3389/fendo.2013.00052 · Cited by 532
A Novel MIF Signaling Pathway Drives the Malignant Character of Pancreatic Cancer by Targeting NR3C2
Yang, S., He, P., Wang, J., Schetter, A., Tang, W., Funamizu, N., Yanaga, K., Uwagawa, T., Satoskar, A. R., Gaedcke, J., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2841 · Cited by 393
“Additionally, tumor cells itself secrete high levels of MIF and thus induce protumorigenic signaling pathway through its autocrine function (10).”
The biological function and significance of CD74 in immune diseases
Su, H., Na, N., Zhang, X., & Zhao, Y. (2017) · Inflammation Research · doi:10.1007/s00011-016-0995-1 · Cited by 306
“The binding of MIF to its receptor complex CD74/CD44 leads to the activation of the extracellular signal regulated kinase (ERK) 1 and 2 in the mitogen-activated protein kinase (MAPK) pathway, and the PI3K/Akt/SRC signal transduction cascade [3, 51, 52], which, in turn, increase cell proliferation, decrease cell apopto…”
BackgroundThe multifaceted roles of the invariant chain CD74 — More than just a chaperone
Schröder, B. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2016.03.026 · Cited by 284
Macrophage Migration Inhibitory Factor in Cardiovascular Disease
Zernecke, A., Bernhagen, J., & Weber, C. (2008) · Circulation · doi:10.1161/circulationaha.107.729125 · Cited by 280
Self-citationA functional heteromeric MIF receptor formed by CD74 and CXCR4
Schwartz, V., Lue, H., Kraemer, S., Korbiel, J., Krohn, R., Ohl, K., Bucala, R., Weber, C., & Bernhagen, J. (2009) · FEBS Letters · doi:10.1016/j.febslet.2009.07.058 · Cited by 247
“Through interaction with CD74, MIF stimulates ERK1/2 and AKT signaling, regulating cell proliferation and survival [16,20,24,26].”
BackgroundSelf-citationEvolving complexity of MIF signaling
Jankauskas, S. S., Wong, D. W. L., Bucala, R., Djudjaj, S., & Boor, P. (2019) · Cellular Signalling · doi:10.1016/j.cellsig.2019.01.006 · Cited by 247
Self-citationChronic inflammation, cancer development and immunotherapy
Wen, Y., Zhu, Y., Zhang, C., Yang, X., Gao, Y., Li, M., Yang, H., Liu, T., & Tang, H. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1040163 · Cited by 229
“…MIF inhibits p53 expression and activates various signaling pathways (JNK-cJun, PI3K-AKT pathways, etc.) to promote cell proliferation, metastasis, angiogenesis, anti-apoptosis and immune suppression, leading to accelerate cancer development (Lue et al., 2007; Lue et al., 2007; Brock et al., 2014).”
BackgroundLi, J.-Y., Ren, K.-K., Zhang, W.-J., Xiao, L., Wu, H.-Y., Liu, Q.-Y., Ding, T., Zhang, X.-C., Nie, W.-J., Ke, Y., et al. (2019) · Stem Cell Research & Therapy · doi:10.1186/s13287-019-1366-y · Cited by 218
“We also found that uPAR [35–38], IL-6 [39], osteopontin (OPN) [40–42], Angiopoietin-2 (ANG-2) [43], HGF [44–46], TGFb1 [47, 48], RBP4 [49], Angiopoietin-1 (ANG-1) [50–52], FAP [53], IL-11 [54, 55], Follistatin [56], DcR3 [57], Galectin-1 [58], MIF [59, 60], IGF-2 [61, 62], MCP-1 [63], and IL-8 [64, 65] were moderately…”
CD74 and intratumoral immune response in breast cancer
Wang, Z.-Q., Milne, K., Webb, J. R., & Watson, P. H. (2017) · Oncotarget · doi:10.18632/oncotarget.8610 · Cited by 202
“MIF is a pleiotropic cytokine produced by many cell types that is associated with promotion of tumor growth and invasiveness [21] through effects on both breast epithelial and immune cells [1].”
Le Hiress, M., Tu, L., Ricard, N., Phan, C., Thuillet, R., Fadel, E., Dorfmüller, P., Montani, D., de Man, F., Humbert, M., et al. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201402-0322oc · Cited by 199
“Stimulation of CD74 initiates a signaling cascade through the sustained and transient activation of the mitogen-activated protein kinases (MAPKs), extracellular signal-regulated kinase (ERK)1 and ERK2, protein kinase B (Akt) and nuclear factor (NF)-κB, leading to leukocytic integrin activation, cell proliferation, and…”
BackgroundSapoznikov, A., Pewzner-Jung, Y., Kalchenko, V., Krauthgamer, R., Shachar, I., & Jung, S. (2008) · Nature Immunology · doi:10.1038/ni1571 · Cited by 183
Targeting MIF in Cancer: Therapeutic Strategies, Current Developments, and Future Opportunities
O'Reilly, C., Doroudian, M., Mawhinney, L., & Donnelly, S. C. (2016) · Medicinal Research Reviews · doi:10.1002/med.21385 · Cited by 180
Twu, O., Dessí, D., Vu, A., Mercer, F., Stevens, G. C., de Miguel, N., Rappelli, P., Cocco, A. R., Clubb, R. T., Fiori, P. L., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1321884111 · Cited by 170
“HuMIF binding of CD74 is also known to activate Akt (43), which can then result in BAD phosphorylation leading to activation of antiapoptotic pathways (44).”
BackgroundBilsborrow, J. B., Doherty, E., Tilstam, P. V., & Bucala, R. (2019) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2019.1656718 · Cited by 168
“MIF signaling promotes cell survival through direct activation of the Akt pathway [30] and prevents apoptosis through inhibition of the tumor suppressor protein p53, a mechanism which is common between many cell types [21].”
BackgroundSelf-citationDai, Z., Zhu, M. M., Peng, Y., Jin, H., Machireddy, N., Qian, Z., Zhang, X., & Zhao, Y.-Y. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201709-1835oc · Cited by 163
Lue, H., Dewor, M., Leng, L., Bucala, R., & Bernhagen, J. (2011) · Cellular Signalling · doi:10.1016/j.cellsig.2010.08.013 · Cited by 162
Self-citationHeinrichs, D., Knauel, M., Offermanns, C., Berres, M.-L., Nellen, A., Leng, L., Schmitz, P., Bucala, R., Trautwein, C., Weber, C., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1107023108 · Cited by 159
Self-citationMacrophage Migration Inhibitory Factor (MIF): Biological Activities and Relation with Cancer
Nobre, C. C. G., de Araújo, J. M. G., Fernandes, T. A. A. D. M., Cobucci, R. N. O., Lanza, D. C. F., Andrade, V. S., & Fernandes, J. V. (2017) · Pathology & Oncology Research · doi:10.1007/s12253-016-0138-6 · Cited by 159
“MIF is constitutively expressed in a variety of immune and non-immune cells such as eosinophils, neutrophils, granulocytes, and monocytes/macrophages, B and T lymphocytes , and endocrine, endothelial, epithelial, and neuronal CD74 MIF Src CD44 ERK 1/2 P Leukocyte chemotaxis AKT PI3K Supression of apoptosis BAD BAX Bcl…”
BackgroundInfluentialJAB1/CSN5: a new player in cell cycle control and cancer
Shackleford, T. J., & Claret, F. X. (2010) · Cell Division · doi:10.1186/1747-1028-5-26 · Cited by 159
“MIF Cytokine with tautomerase and oxidoreductases activities Inhibition of MIF secretion Inhibits MIF-mediated AKT signaling [112]”
BackgroundDual role of macrophage migration inhibitory factor (MIF) in human breast cancer
Verjans, E., Noetzel, E., Bektas, N., Schütz, A. K., Lue, H., Lennartz, B., Hartmann, A., Dahl, E., & Bernhagen, J. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-230 · Cited by 150
“MIF is overexpressed in various breast cancer cell lines and human breast cancer tissue but its functional role in the pathogenesis of this tumour entity is poorly understood [12,21,31].”
MethodInfluentialSelf-citationMacrophage migration inhibitory factor promotes cyst growth in polycystic kidney disease
Chen, L., Zhou, X., Fan, L. X., Yao, Y., Swenson-Fields, K. I., Gadjeva, M., Wallace, D. P., Peters, D. J. M., Yu, A., Grantham, J. J., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80467 · Cited by 139
Overexpression of macrophage migration inhibitory factor induces angiogenesis in human breast cancer
Xu, X., Wang, B., Ye, C., Chen, Y., Lin, Y., Huang, X., Zhang, Y., & Wang, S. (2008) · Cancer Letters · doi:10.1016/j.canlet.2007.11.028 · Cited by 151
Chatterjee, M., Borst, O., Walker, B., Fotinos, A., Vogel, S., Seizer, P., Mack, A. F., Alampour‐Rajabi, S., Rath, D., Geisler, T., et al. (2014) · Circulation Research · doi:10.1161/circresaha.115.305171 · Cited by 131
“Previously, MIF was identified to promote cell survival by activating the Akt pathway.(28,29) In human rhabdomyosarcoma cell lines, which secrete MIF(20) but do not express CXCR2 and CD74 like platelets, MIF triggers phosphorylation of MAPK p42/44 and Akt, enhances adhesion to fibronectin and human umbilical vein endo…”
BackgroundSelf-citationTargeting SRC in glioblastoma tumors and brain metastases: Rationale and preclinical studies
Ahluwalia, M. S., de Groot, J., Liu, W., & Gladson, C. L. (2010) · Cancer Letters · doi:10.1016/j.canlet.2010.08.014 · Cited by 139
MIF family proteins in genitourinary cancer: tumorigenic roles and therapeutic potential
Penticuff, J. C., Woolbright, B. L., Sielecki, T. M., Weir, S. J., & Taylor, J. A. (2019) · Nature Reviews Urology · doi:10.1038/s41585-019-0171-9 · Cited by 132
Chen, H., Chuang, Y., Lin, Y.-S., Liu, H., Liu, C., Perng, G., & Yeh, T. (2016) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0004828 · Cited by 139
Schulz‐Heddergott, R., Marchenko, N. D., Holembowski, L., Fingerle‐Rowson, G., Pesic, M. H., Zender, L., Dobbelstein, M., & Moll, U. M. (2012) · The Journal of Experimental Medicine · doi:10.1084/jem.20111117 · Cited by 118
Self-citationArrest Functions of the MIF Ligand/Receptor Axes in Atherogenesis
Tillmann, S., Bernhagen, J., & Noels, H. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00115 · Cited by 125
“Furthermore, a CD74/Src/PI3K/AKT pathway links MIF to the phosphorylation of the pro-apoptotic proteins BAD and FOXO3a, providing a survival signal (Lue et al., 2007).”
BackgroundSelf-citationControl of p53 and NF-κB signaling by WIP1 and MIF: Role in cellular senescence and organismal aging
Salminen, A., & Kaarniranta, K. (2011) · Cellular Signalling · doi:10.1016/j.cellsig.2010.10.012 · Cited by 111
Fan, H., Hall, P., Santos, L. L., Gregory, J. L., Fingerle‐Rowson, G., Bucala, R., Morand, E. F., & Hickey, M. J. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003713 · Cited by 114
“For example, MIF deficiency impairs MAPK signaling entrained by the proinflammatory cytokines IL-1 and TNF or by Ag-specific T cell activation (31–33), and MIF also activates the PI3K–Akt pathway (34, 35).”
Self-citationCheng, Q., McKeown, S. J., Santos, L., Santiago, F. S., Khachigian, L. M., Morand, E. F., & Hickey, M. J. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0904104 · Cited by 110
Ohta, S., Misawa, A., Fukaya, R., Inoue, S., Kanemura, Y., Okano, H., Kawakami, Y., & Toda, M. (2012) · Journal of Cell Science · doi:10.1242/jcs.102210 · Cited by 110
“MIF has been reported to activate many signaling pathways including the Erk and Akt pathways in many cells (Meyer-Siegler et al., 2006; Shi et al., 2006; Lue et al., 2007).”
BackgroundZeiner, P. S., Preusse, C., Blank, A., Zachskorn, C., Baumgarten, P., Caspary, L., Braczynski, A. K., Weissenberger, J., Bratzke, H., Reiß, S., et al. (2015) · Brain Pathology · doi:10.1111/bpa.12194 · Cited by 108
“Thus acting as a chemokine, MIF may recruit myeloid cells and influence M1/M2 polarization in intratumoral immune cells (9, 11, 20).”
BackgroundMIF as a Disease Target: ISO-1 as a Proof-of-Concept Therapeutic
Al‐Abed, Y., & VanPatten, S. (2010) · Future Medicinal Chemistry · doi:10.4155/fmc.10.281 · Cited by 107
Klemke, L., Oliveira, T. D., Witt, D., Winkler, N., Bohnenberger, H., Bucala, R., Conradi, L., & Schulz‐Heddergott, R. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03426-z · Cited by 114
Self-citationmiR-451a is underexpressed and targets AKT/mTOR pathway in papillary thyroid carcinoma
Minna, E., Romeo, P., Dugo, M., Cecco, L. D., Todoerti, K., Pilotti, S., Perrone, F., Seregni, E. C., Agnelli, L., Neri, A., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7262 · Cited by 107
Macrophage migration inhibitory factor: A key cytokine in RA, SLE and atherosclerosis
Santos, L. L., & Morand, E. F. (2008) · Clinica Chimica Acta · doi:10.1016/j.cca.2008.09.014 · Cited by 106
“[43,44,48], as well as phosphoinositide-3-kinase (PI3 k) [49,50].”
Macrophage migration inhibitory factor involvement in breast cancer (Review)
RICHARD, V., Kindt, N., & Saussez, S. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3185 · Cited by 94
“Lue et al (31) showed on various breast cancer cell lines that the interaction of MIF with its membrane receptor CD74 induced activation of PI3K/Akt signaling pathway, promoting cell survival.”
Ouertatani-Sakouhi, H., El-Turk, F., Fauvet, B., Cho, M., Karpinar, D. P., Roy, D. L., Dewor, M., Roger, T., Bernhagen, J., Calandra, T., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.113951 · Cited by 95
Self-citationCurrent developments of macrophage migration inhibitory factor (MIF) inhibitors
Xu, L., Li, Y., Sun, H., Zhen, X., Qiao, C., Tian, S., & Hou, T. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2012.12.013 · Cited by 92
CXCR7 Targeting and Its Major Disease Relevance
Wang, C., Chen, W., & Shen, J. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00641 · Cited by 100
“With the help of co-receptor CD44, MIF can induce signaling through CD74 to activate tyrosine kinases and the PI3K/AKT pathway (Shi et al., 2006; Lue et al., 2007).”
BackgroundMcClelland, M., Zhao, L., Carskadon, S. L., & Arenberg, D. A. (2009) · American Journal Of Pathology · doi:10.2353/ajpath.2009.080463 · Cited by 98
Cardioprotection Through S -Nitros(yl)ation of Macrophage Migration Inhibitory Factor
Luedike, P., Hendgen-Cotta, U. B., Sobierajski, J., Totzeck, M., Reeh, M., Dewor, M., Lue, H., Krisp, C., Wolters, D., Kelm, M., et al. (2012) · Circulation · doi:10.1161/circulationaha.111.069104 · Cited by 90
Self-citationBritton, C., Poznansky, M. C., & Reeves, P. (2021) · The FASEB Journal · doi:10.1096/fj.202001273r · Cited by 95
Zhao, J., Li, L., Liu, Q., Liu, P., Li, S., Yang, D., Chen, Y., Pagnotta, S., Favery, B., Abad, P., et al. (2019) · Journal of Experimental Botany · doi:10.1093/jxb/erz348 · Cited by 92
Ceccarelli, J., Delfino, L., Zappia, E., Castellani, P., Borghi, M., Ferrini, S., Tosetti, F., & Rubartelli, A. (2008) · International Journal of Cancer · doi:10.1002/ijc.23709 · Cited by 92
CD74 and macrophage migration inhibitory factor as therapeutic targets in gastric cancer
Zheng, Y. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i18.2253 · Cited by 85
The Multitasking Potential of Alarmins and Atypical Chemokines
Kapurniotu, A., Gökçe, Ö., & Bernhagen, J. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00003 · Cited by 87
Self-citationFarr, L., Ghosh, S., Jiang, N., Watanabe, K., Parlak, M., Bucala, R., & Moonah, S. (2020) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2020.01.009 · Cited by 83
“MIF Stimulation, Cell Proliferation, and Wound Healing Assays MIF stimulation was performed as previously described.(27) CD74þ/þ and CD74 HCT116 colonic epithelial cells (10(6)/mL) were stimulated with MIF at 100 ng/mL.”
BackgroundMethodSelf-citationMechanisms of Disease: macrophage migration inhibitory factor in SLE, RA and atherosclerosis
Ayoub, S., Hickey, M. J., & Morand, E. F. (2008) · Nature Clinical Practice Rheumatology · doi:10.1038/ncprheum0701 · Cited by 90
Alinari, L., Yu, B., Christian, B. A., Yan, F., Shin, J. D., Lapalombella, R., Hertlein, E. K., Lustberg, M. E., Quinion, C. D., Zhang, X., et al. (2011) · Blood · doi:10.1182/blood-2010-08-303354 · Cited by 85
Macrophage migration inhibitory factor in myocardial ischaemia/reperfusion injury
Rassaf, T., Weber, C., & Bernhagen, J. (2014) · Cardiovascular Research · doi:10.1093/cvr/cvu071 · Cited by 85
“Moreover, later studies showed that JAB1 controls autocrine MIF-mediated Akt signalling by inhibition of MIF secretion in HeLa cervix carcinoma cells.(39) We demonstrated that this interaction critically depends on Cys81 of the amino acid structure of MIF, and that pin-pointed S-nitros(yl)ation at this cysteine residu…”
BackgroundSelf-citationChemokine-like functions of MIF in atherosclerosis
Schober, A., Bernhagen, J., & Weber, C. (2008) · Journal of Molecular Medicine · doi:10.1007/s00109-008-0334-2 · Cited by 96
Self-citationMangano, K., Mazzon, E., Basile, M. S., Marco, R. D., Bramanti, P., Mammana, S., Petralia, M. C., Fagone, P., & Nicoletti, F. (2018) · Oncotarget · doi:10.18632/oncotarget.24885 · Cited by 84
Wu, J., Akkuratov, E. E., Bai, Y., Gaskill, C. M., Askari, A., & Liu, L. (2013) · Biochemistry · doi:10.1021/bi4011804 · Cited by 86
The role of macrophage inhibitory factor in tumorigenesis and central nervous system tumors
Bach, J., Deuster, O., Balzer‐Geldsetzer, M., Meyer, B., Dodel, R., & Bacher, M. (2009) · Cancer · doi:10.1002/cncr.24245 · Cited by 80
“These data were confirmed by Lue et al in a study in which MIF was shown to promote cell survival by activation of the Akt pathway.(40) In addition, the ERK activation and induction pathways for cyclooxygenase-2 (COX-2) are both expressed in colon carcinoma and are believed to be essential.”
ResultMIF family cytokines in cardiovascular diseases and prospects for precision-based therapeutics
Tilstam, P. V., Qi, D., Leng, L., Young, L. H., & Bucala, R. (2017) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2017.1336227 · Cited by 78
“Importantly, MIF enhances cellular responses by sustaining cell survival through inhibition of p53 or pAkt-dependent activation-induced apoptosis [25,26].”
BackgroundSelf-citationInsights into the role of macrophage migration inhibitory factor in obesity and insulin resistance
Finucane, O. M., Reynolds, C. M., McGillicuddy, F. C., & Roche, H. M. (2012) · Proceedings of The Nutrition Society · doi:10.1017/s0029665112000730 · Cited by 94
“In this regard, MIF can inhibit immunosuppressive glucocorticoids, promote secretion of a variety of cytokines including TNF-a , IL-2, IL-6, IL-8, interferon-gg , IL-1 b and inhibit IL-10 propagating a pro-inflammatory response (105–108) .”
MIF, CD74 and other partners in kidney disease: Tales of a promiscuous couple
Sánchez-Niño, M. D., Sanz, A. B., Ruiz‐Andrés, O., Poveda, J., Izquierdo, M. C., Selgas, R., Egido, J., & Ortíz, A. (2012) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2012.08.001 · Cited by 77
“secretion [46] and MIF negatively regulates JAB1-controlled pathways [10].”
BackgroundKim, M. J., Kim, W. S., Kim, D. O., Byun, J., Huy, H., Lee, S. Y., Song, H. Y., Park, Y., Kim, T., Yoon, S. R., et al. (2017) · Cellular Signalling · doi:10.1016/j.cellsig.2017.03.007 · Cited by 80
Macrophage Migration Inhibitory Factor: A Noncanonical Chemokine Important in Atherosclerosis
Noels, H., Bernhagen, J., & Weber, C. (2009) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2009.05.002 · Cited by 78
“This MIF-induced Akt signaling is furthermore negatively regulated by JAB-1 through inhibition of MIF secretion (Lue et al. 2007).”
BackgroundInfluentialSelf-citationRoger, T., Delaloye, J., Chanson, A.-L., Giddey, M., Roy, D. L., & Calandra, T. (2012) · The Journal of Infectious Diseases · doi:10.1093/infdis/jis673 · Cited by 81
“phosphoinositide-3-kinase/Akt (PI3K/Akt) signaling pathways [6–8].”
MIF, MIF Alleles, and Prospects for Therapeutic Intervention in Autoimmunity
Bucala, R. (2012) · Journal of Clinical Immunology · doi:10.1007/s10875-012-9781-1 · Cited by 72
Self-citationHussain, F., Freissmuth, M., Völkel, D., Thiele, M., Douillard, P., Antoine, G., Thurner, P., Ehrlich, H. J., Schwarz, H., Scheiflinger, F., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0988 · Cited by 72
“In vitro, the selected candidate antibodies BaxG03, BaxB01, and BaxM159 reduced cell growth and viability by inhibiting MIF-induced phosphorylation of the central kinases p44/42 mitogen-activated protein kinase [extracellular signal–regulated kinase-1 and -2 (ERK1/2)] and protein kinase B (AKT).”
BackgroundInfluentialSelf-citationMIF: Implications in the Pathoetiology of Systemic Lupus Erythematosus
Lang, T., Foote, A., Lee, J. P. W., Morand, E. F., & Harris, J. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00577 · Cited by 73
“Sustained activation of ERK is attained via c-Jun activation domain binding protein (JAB-1) (58).”
BackgroundZhang, J., Tao, L., Yang, M., Xu, D., Jiang, S., Fu, X., Liu, D., Huo, Y., Liu, W., Yang, J., et al. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.03.016 · Cited by 81
Cell signalling in macrophages, the principal innate immune effector cells of rheumatoid arthritis
Drexler, S. K., Kong, P. L., Wales, J., & Foxwell, B. M. J. (2008) · Arthritis Research & Therapy · doi:10.1186/ar2481 · Cited by 78
Oliveira, C. S., de Bock, C. E., Molloy, T. J., Sadeqzadeh, E., Geng, X., Hersey, P., Zhang, X. D., & Thorne, R. F. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-630 · Cited by 70
“Depending on the cellular context, binding of MIF to its known cell surface receptors can lead to activation of two fundamental signalling axes, namely the mitogen-activated protein kinase (MAPK) pathway and PI3K/Akt signalling [14,21-23].”
BackgroundSu, Y., Wang, Y., Zhou, Y., Zhu, Z., Zhang, Q., Zhang, X., Wang, W., Gu, X., Guo, A., & Wang, Y. (2016) · Oncotarget · doi:10.18632/oncotarget.13739 · Cited by 77
“Whether phosphorylation of ERK1/2 or PI3K is implicated in activation of Pla2g2a deserves further clarification.”
BackgroundInfluentialStein, A., Panjwani, A., Sison, C. P., Rosen, L. M., Chugh, R., Metz, C. N., Bank, M. A., & Bloom, O. (2013) · Archives of Physical Medicine and Rehabilitation · doi:10.1016/j.apmr.2013.04.004 · Cited by 74
Hallmarks of Cancer Affected by the MIF Cytokine Family
Barthelmess, R. M., Stijlemans, B., & Ginderachter, J. A. V. (2023) · Cancers · doi:10.3390/cancers15020395 · Cited by 83
Rendon, B. E., Willer, S. S., Zundel, W., & Mitchell, R. A. (2009) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2009.01.001 · Cited by 70
“Extracellular MIF is shown to functionally regulate the activities of intracellular CSN5 (Berndt et al., 2008; Kleemann et al., 2000; Kleemann et al., 2002; Lue et al., 2007; Meyer-Siegler et al., 2006).”
Soluble CD74 Reroutes MIF/CXCR4/AKT‐Mediated Survival of Cardiac Myofibroblasts to Necroptosis
Soppert, J., Kraemer, S., Beckers, C., Averdunk, L., Möllmann, J., Denecke, B., Goetzenich, A., Marx, G., Bernhagen, J., & Stoppe, C. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.118.009384 · Cited by 70
Self-citationWirtz, T. H., Saal, A., Bergmann, I., Fischer, P., Heinrichs, D., Brandt, E. F., Koenen, M. T., Djudjaj, S., Schneider, K. M., Boor, P., et al. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15622 · Cited by 66
“Here, MIF/CD74 signalling was identified to regulate tumour cell survival (Lue et al., 2007).”
BackgroundResultSelf-citationChoudhary, S., Hegde, P., Pruitt, J. R., Sielecki, T. M., Choudhary, D., Scarpato, K. R., DeGraff, D. J., Pilbeam, C. C., & Taylor, J. A. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt239 · Cited by 65
Platelets are a previously unrecognised source of MIF
Wirtz, T., Bucala, R., von Hundelshausen, P., Strüßmann, T., Tillmann, S., & Bernhagen, J. (2013) · Thrombosis and Haemostasis · doi:10.1160/th13-01-0049 · Cited by 63
“Additionally, heteromeric CD74/CXCR MIF receptor complexes have been implicated in inflammatory regulation by MIF (20-22).”
BackgroundSelf-citationThiele, M., Donnelly, S. C., & Mitchell, R. A. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005475 · Cited by 63
“…of the PI3K/AKT pathway led to inactivation of pro-apoptotic proteins in mouse embryonic fibroblasts and NIH/3T3 (immortalized fibroblasts), HeLa (cervical carcinoma), and various breast cancer cell lines 14 and expression of anti-apoptotic proteins in chronic lymphocytic leukemia B cells.”
Self-citationMacrophage Migration Inhibitory Factor: a Potential Marker for Cancer Diagnosis and Therapy
Babu, S. N., Chetal, G., & Kumar, S. (2012) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2012.13.5.1737 · Cited by 67
“Along with this AKT pathway is also activated by MIF (Lue et al., 2007).”
BackgroundSerum biomarker profiles and response to neoadjuvant chemotherapy for locally advanced breast cancer
Nolen, B. M., Marks, J. R., Ta'san, S., Rand, A., Luong, T. M., Wang, Y., Blackwell, K., & Lokshin, A. E. (2008) · Breast Cancer Research · doi:10.1186/bcr2096 · Cited by 60
“unknown, but MIF has been implicated in tumor cell survival pathways [47].”
BackgroundTargeting Adipokines in Obesity-Related Tumors
Pu, X., & Chen, D. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.685923 · Cited by 64
Ouertatani-Sakouhi, H., El-Turk, F., Fauvet, B., Roger, T., Roy, D. L., Karpinar, D. P., Leng, L., Bucala, R., Zweckstetter, M., Calandra, T., et al. (2009) · Biochemistry · doi:10.1021/bi900957e · Cited by 59
“Previous studies have shown that MIF promotes cell survival through activation of the PI3K/Akt pathway(48).”
BackgroundSelf-citationThiele, M., Kerschbaumer, R. J., Tam, F. W. K., Völkel, D., Douillard, P., Schinagl, A., Kühnel, H., Smith, J., McDaid, J., Bhangal, G., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1500572 · Cited by 62
“tributing to the maintenance of inflammatory processes (3, 8).”
BackgroundSelf-citationLi, G., Xie, J., Lei, X., & Zhang, L. (2009) · World Journal of Gastroenterology · doi:10.3748/wjg.15.5541 · Cited by 59
Role for CD74 and CXCR4 in clathrin-dependent endocytosis of the cytokine MIF
Schwartz, V., Krüttgen, A., Weis, J., Weber, C., Ostendorf, T., Lue, H., & Bernhagen, J. (2011) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2011.08.006 · Cited by 58
“Endogenous MIF is known to activate the AKT pathway by an autocrine mechanism (Lue et al., 2007), thus indicating that CPZ may have interfered with autocrine MIF effects on the AKT pathway.”
BackgroundSelf-citationInvolvement of macrophage migration inhibitory factor and its receptor (CD74) in human breast cancer
RICHARD, V., Kindt, N., Decaestecker, C., Gabius, H., LAURENT, G., Noël, J., & Saussez, S. (2014) · Oncology Reports · doi:10.3892/or.2014.3272 · Cited by 59
Dewor, M., Steffens, G. C. M., Krohn, R. M., Weber, C., Baron, J. M., & Bernhagen, J. (2007) · FEBS Letters · doi:10.1016/j.febslet.2007.08.071 · Cited by 64
Self-citationInhibition of atherogenesis by the COP9 signalosome subunit 5 in vivo
Asare, Y., Ommer-Bläsius, M., Azombo, F. A., Alampour‐Rajabi, S., Sternkopf, M., Sanati, M., Gijbels, M. J., Schmitz, C., Sinitski, D., Tilstam, P. V., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1618411114 · Cited by 62
“With respect to CSN5, the clearness of the identified antiatherogenic (and antiinflammatory) effects is remarkable, as previous studies have also linked CSN5 to proinflammatory JNK/ AP1 signaling and proatherogenic LFA-1 integrin activation while counteracting inflammatory MIF activity (14–16).”
BackgroundInfluentialSelf-citationExpression of CD74 in high grade gliomas: a potential role in temozolomide resistance
Kitange, G. J., Carlson, B. L., Schroeder, M. A., Decker, P. A., Morlan, B. W., Wu, W., Ballman, K. V., Giannini, C., & Sarkaria, J. N. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0186-9 · Cited by 56
“These findings suggest that CD74 signaling via MIF activation may provide important mitogenic and survival signals through the Src, MAPK and Akt signaling pathways.”
InfluentialLerch, J. K., Puga, D. A., Bloom, O., & Popovich, P. G. (2014) · Seminars in Immunology · doi:10.1016/j.smim.2014.03.004 · Cited by 57
Yuan, H., Zhou, Y., Lee, M., Zhang, Y., & Li, W. (2016) · Acta Biomaterialia · doi:10.1016/j.actbio.2016.06.034 · Cited by 58
Liu, G., Claret, F. X., Zhou, F., & Pan, Y. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00135 · Cited by 64
“…mechanism between Jab1/COPS5 and PI3K/AKT pathway has been identified that Jab1/COPS5 inhibits MIF (autocrine macrophage migration inhibitory factor) secretion and its autocrine pro-survival activities and subsequently controls MIF mediated activation of PI3K/AKT signaling (Lue et al., 2007).”
BackgroundPleiotropic role of macrophage migration inhibitory factor in cancer.
Guda, M. R., Rashid, M. A., Asuthkar, S., Jalasutram, A., Caniglia, J. L., Tsung, A. J., & Velpula, K. K. (2019) · PubMed Central · Cited by 56
Mun, S. H., Won, H. Y., Hernández, P., Aguila, H. L., & Lee, S. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1787 · Cited by 58
“To date, MIF has been reported to inhibit apoptosis and promote tumor cell survival through the AKT pathway((59)) in various cell types.”
BackgroundCD74 expression and its therapeutic potential in thyroid carcinoma
Cheng, S., Liu, C., Chen, M., Chien, M.-N., Leung, C.-H., Lin, C., Hsu, Y., & Lee, J.-J. (2015) · Endocrine Related Cancer · doi:10.1530/erc-14-0269 · Cited by 54
Milatuzumab – a promising new immunotherapeutic agent
Berkova, Z., Tao, R.-H., & Samaniego, F. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903463854 · Cited by 59
“Activation of Akt leads to phosphorylation of BAD and Foxo3a and effectively inhibits apoptosis [36].”
BackgroundSantos, L. L., Dacumos, A., Yamana, J., Sharma, L., & Morand, E. F. (2008) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2008.03639.x · Cited by 57
Macrophage migration inhibitory factor deficiency in chronic obstructive pulmonary disease
Sauler, M., Leng, L., Trentalange, M. J., Haslip, M., Shan, P., Piecychna, M., Zhang, Y., Andrews, N., Mannam, P., Allore, H. G., et al. (2014) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00284.2013 · Cited by 54
“CD74 engages CD44 to stimulate Src family kinases, which leads downstream to AKT/ERK activation (37, 52).”
BackgroundSelf-citationGao, Y., Hou, R., Liu, F., Liu, H., Fei, Q., Han, Y., Cai, R., Peng, C. Y., & Qi, Y. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26248 · Cited by 56
Gadjeva, M. G., Nagashima, J., Zaidi, T., Mitchell, R. A., & Pier, G. B. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1000826 · Cited by 53
Metadata
- Authors
- Lue, H., Thiele, M., Franz, J., Dahl, E., Speckgens, S., Leng, L., Fingerle-Rowson, G., Bucala, R., Lüscher, B., & Bernhagen, J.
- Affiliations
- Universitätsklinikum Aachen (DE)
- Yale University (US)
- Corresponding author
- Bernhagen, J
- Venue
- Oncogene
- Published
- 2007-02-19
- Volume
- 26
- Issue
- 35
- Pages
- 5046-5059
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2047308155
- Cited by
- 385
- References
- 49
- Citations by year
- 2026: 10 · 2025: 19 · 2024: 14 · 2023: 15 · 2022: 23 · 2021: 29 · 2020: 14 · 2019: 24 · 2018: 20 · 2017: 20 · 2016: 23 · 2015: 27 · 2014: 23 · 2013: 20 · 2012: 29
- FWCI
- 7.72
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Oncogene (publishedVersion)
- PubMed (publishedVersion)
- RWTH Publications (RWTH Aachen) (submittedVersion)
- Funders
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases (AI43210)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (AR49610, R01AR049610)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Macrophage Migration Inhibitory Factor
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Keywords
- macrophage migration inhibitory factor, Akt signaling, PI3K/Akt signaling, cell survival, apoptosis inhibition, CD74, autocrine signaling, tumor cell survival, breast cancer, PTEN, Bad, FOXO3, p53-independent apoptosis, etoposide-induced apoptosis, Src kinase, tumor microenvironment
- MeSH terms
- COP9 Signalosome Complex, Animals, Antigens, Differentiation, B-Lymphocyte, Histocompatibility Antigens Class II, Breast Neoplasms, Cell Survival, Humans, Macrophage Migration-Inhibitory Factors, Neoplasms, Peptide Hydrolases, Phosphorylation, src-Family Kinases, Phosphatidylinositol 3-Kinases, Autocrine Communication, Cell Line, Tumor, Intracellular Signaling Peptides and Proteins, Proto-Oncogene Proteins c-akt, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.